Novel disease-specific promoters for use in gene therapy for Parkinson's disease.

Research output: Contribution to journalArticle


Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91-100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.


Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurosciences


  • Promoter, Parkinson's disease, Gene therapy, Neuron-specific
Original languageEnglish
Pages (from-to)29-34
JournalNeuroscience Letters
Issue number1
Publication statusPublished - 2012
Publication categoryResearch

Related research output

Erika Elgstrand, 2013, Department of Experimental Medical Science, Lund Univeristy. 116 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)